TheraRadar
Data updated: May 26, 2026

ISRADIPINE

Calcium Channel Antagonists
Cardiovascular Approved 2006-01-05

ISRADIPINE is indicated for the treatment of Hypertension.

Source: FDA Label • ELITE LABS INC
3
Indications
--
Phase 3 Trials
20
Years on Market

Details

Status
Prescription
First Approved
2006-01-05
Routes
ORAL
Dosage Forms
CAPSULE, TABLET, EXTENDED RELEASE

ISRADIPINE Approval History

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
6 FDA actions from 2006 to 2015
Nov 2015 ORIGINAL
Update · Not Applicable
Apr 2006 ORIGINAL
Update
Jan 2006 ORIGINAL
Update

What ISRADIPINE Treats

1 indications

ISRADIPINE is approved for 1 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertension
Source: FDA Label

ISRADIPINE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ISRADIPINE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACEBUTOLOL HYDROCHLORIDE
ACEBUTOLOL HYDROCHLORIDE
1 shared
PHARMOBEDIENT
Shared indications:
ALDACTONE
SPIRONOLACTONE
1 shared
Pfizer
Shared indications:
ALISKIREN HEMIFUMARATE
ALISKIREN HEMIFUMARATE
1 shared
PH HEALTH
Shared indications:
📋

Clinical Trial Registry

3 trials
Trial Sponsor ID Phase Status Title
NCT02168842 results posted STEADY-PD III U01NS080818-01A1, U01NS080840-01A1 Ph 3 completed Efficacy of Isradipine in Early Parkinson Disease
NCT01895270 results posted R21DA035325 R21DA035325 Ph 1, Ph 2 completed Improving Buprenorphine Detoxification Outcomes With Isradipine
NCT01784666 Isradipine results posted 2012-P-002449/1 Ph 2 terminated Adjunctive Isradipine for the Treatment of Bipolar Depression
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ISRADIPINE FDA Label Details

Indications & Usage

ISRADIPINE is indicated for the treatment of Hypertension.

Looking for the branded version?

DYNACIRC

Full clinical data, patents, trials, and competitive landscape for isradipine.

See DYNACIRC

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.